By Fineline Cube 
Hansoh Pharmaceutical Group Co., Ltd. (HKG: 3692) announced that China’s National Medical Products Administration (NMPA) has approved a new indication for Uplizna® (inebilizumab), a CD19-targeting monoclonal antibody, for the treatment of anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody-positive generalized myasthenia gravis (gMG) in combination with standard therapies. This marks the third NMPA approval for Uplizna in China, following prior nods for aquaporin-4 (AQP4) antibody-positive neuromyelitis optica spectrum disorder (NMOSD) in March 2022 and IgG4-related disease (IgG4-RD) in September 2025.
Regulatory & Commercial Timeline
| Indication | NMPA Approval Date | Significance |
|---|---|---|
| NMOSD (AQP4+) | March 2022 | First approval in China; established CD19 depletion in neuroimmunology |
| IgG4-RD | September 2025 | Expanded into fibroinflammatory systemic disease |
| gMG (AChR+/MuSK+) | March 2026 | Third indication; addresses high-unmet-need autoimmune neuromuscular disorder |
Uplizna is now China’s only approved CD19-depleting therapy across multiple B-cell–mediated conditions.
Drug Profile & Mechanism
- Target: CD19—a pan-B-cell surface marker expressed from pro-B to mature B cells (but not plasma cells)
- Mechanism: Depletes pathogenic B-cell subsets driving autoantibody production while sparing long-lived plasma cells, potentially preserving protective immunity
- Differentiation vs. CD20 mAbs: Broader B-cell coverage (including CD20-negative plasmablasts) may enhance efficacy in antibody-mediated diseases like gMG and NMOSD
In gMG—a condition affecting ~60,000 patients in China—Uplizna offers a targeted alternative to chronic immunosuppressants and FcRn inhibitors.
Licensing & Strategic Background
- Originator: Viela Bio Inc. (U.S.), acquired by Astellas in 2021
- Deal Terms: Hansoh secured exclusive development and commercialization rights in China in May 2019 for $220 million, covering NMOSD, gMG, IgG4-RD, and hematological malignancies
- Franchise Value: Three NMPA approvals validate Hansoh’s strategic bet on CD19 biology and its ability to execute rapid regulatory expansion
With gMG joining NMOSD and IgG4-RD, Uplizna is positioned as a platform therapy for B-cell–driven autoimmune disorders.
Market Implications
- gMG Treatment Gap: Few biologics approved in China; most patients rely on corticosteroids, azathioprine, or off-label rituximab
- Pricing Leverage: Orphan drug status and multi-indication use support premium reimbursement
- Commercial Synergy: Leverages Hansoh’s established neuroimmunology sales force and hospital access from NMOSD launch
Annual sales potential across all three indications could exceed ¥1.5 billion ($215M) by 2028, analysts estimate.
Forward‑Looking Statements
This brief contains forward-looking statements regarding market adoption, reimbursement, and clinical uptake. Actual results may vary due to prescribing patterns, competitive entries, and healthcare policy changes.-Fineline Info & Tech